Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979205 | 0.85 | HPGD (0.48) | ALDH1A1HPGDTTRTSHRTP53 | |
| SCHEMBL842203 | 0.83 | CYP11B1 (0.42) | ALDH1A1HPGDMAPTS1PR1S1PR3 | |
| SCHEMBL31227427 | 0.83 | S1PR3 (0.41) | ALDH1A1HPGDS1PR1S1PR3 | |
| SCHEMBL4580974 | 0.83 | S1PR3 (0.41) | ALDH1A1HPGDS1PR1S1PR3 | |
| SCHEMBL17784099 | 0.83 | GAA (0.41) | ALDH1A1HPGDKDM4EGAAXDH | |
| SCHEMBL21125466 | 0.82 | HPGD (0.54) | ALDH1A1HPGDMAPTL3MBTL1 | |
| SCHEMBL29472005 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDTSHRTP53KDM4E | |
| SCHEMBL4844022 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDTSHRTP53KDM4E | |
| SCHEMBL20787536 | 0.79 | HDAC8 (0.47) | HPGDTSHRCA2S1PR1S1PR3 | |
| SCHEMBL2143380 | 0.79 | NOTUM (0.54) | ALDH1A1HPGDTSHRTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| WO-2025015045-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| CN-1968945-A | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH CORP (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1756087-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | Wyeth (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006009653-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009653-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | ALDH1A1 1765/4885HPGD 1149/4885TTR 2822/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ALDH1A1 4385/4885HPGD 2141/4885TTR 4868/4885 |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | ALDH1A1 1765/4885HPGD 1149/4885TTR 2822/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | ALDH1A1 385/4885HPGD 943/4885TTR 651/4885 |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | BACE1, BACE2, APP | ALDH1A1 2182/4885HPGD 2108/4885TTR 649/4885 |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | ALDH1A1 1765/4885HPGD 1149/4885TTR 2822/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | ALDH1A1 1765/4885HPGD 1149/4885TTR 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.